News
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Those battling severe asthma, upper respiratory tract diseases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis and ...
20h
Dealbreaker on MSNMerck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona PharmaVerona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results